Peptide

Lilly expands manufacturing footprint in Ireland with $1.8 billion investment

Retrieved on: 
Thursday, September 12, 2024
Innovation, Investment, Water, International Society, Patient, LLY, Alzheimer's disease, Obesity, AI, Disease, Peptide, Workforce, Government, Republic of Ireland, Eli Lilly and Company, Robotics, Diabetes, County council, Machine learning, Employment, Pharmaceutical industry

INDIANAPOLIS, Sept. 12, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a $1 billion expansion of its Limerick, Ireland, manufacturing site to increase production of biologic active ingredients, including those for its recently approved treatment for early symptomatic Alzheimer's disease. The company also unveiled its new $800 million facility expansion in Kinsale, Ireland, which began making medicines last year to meet demand for Lilly's latest diabetes and obesity treatments.

Key Points: 
  • This additional investment is part of the most ambitious manufacturing expansion agenda in the company's history.
  • Since 2020, Lilly has committed more than $20 billion to build, expand and acquire manufacturing facilities in the U.S. and Europe.
  • Today's announcement brings Lilly's total Limerick investment to $2 billion, doubling the investment the company announced in March 2023.
  • The site employs a digital-first process that integrates continuous manufacturing technology to create a new manufacturing platform for creating complex peptides.

COSRX Debuts Viral The 6 Peptide Skin Booster Serum at ULTA Stores Across the US with Experiential Pop Ups in California and New York

Retrieved on: 
Thursday, September 12, 2024
Peptide, Ulta Beauty, Skin, City, Guilt, Glass, ULTA, Serum, Neck, Face, Ulta, Electric motor

NEW YORK, Sept. 11, 2024 /PRNewswire/ -- COSRX celebrates the in-store debut of the consistently sold-out, viral The 6 Peptide Skin Booster Serum by hosting experiential consumer one-day pop up events across six ULTA Beauty stores in the US.

Key Points: 
  • NEW YORK, Sept. 11, 2024 /PRNewswire/ -- COSRX celebrates the in-store debut of the consistently sold-out, viral The 6 Peptide Skin Booster Serum by hosting experiential consumer one-day pop up events across six ULTA Beauty stores in the US.
  • Starting in California on September 12, and ending in New York on September 21, COSRX is welcoming fans of the brand to experience the best-selling peptide serum along with photo-worthy moments, custom tote bags, collagen popsicles, freebies and more!
  • This derm-favorite Peptide Serum is a unique blend of six peptides which work wonders in addressing various skin concerns, making it the go-to solution for those seeking smooth, luminous skin.
  • Its lightweight, water-based formula layers seamlessly into any routine, providing a boosting effect that takes your skin to the next level.

Collagen tripeptides: a new era of collagen drinks

Retrieved on: 
Wednesday, September 11, 2024
Arthralgia, USD, Walking, Dicarboxylic acid, Tablet, Drink, Skin care, Clinical trial, Skin, Tissue, Elasticity, Growth, Blood, Food, Peptide, Absorption, Ultimate tensile strength, Human, Maxi, Health, Cartilage, TCI, Nutrient, Capsule, Double, Dietary supplement, Tendon

TAIPEI, Sept. 11, 2024 /PRNewswire/ -- The 2023 global collagen market was valued at USD 9.76 billion and is projected to experience a compound annual growth rate (CAGR) of 9.6% from 2024 to 2030. This growth is fueled by the increasing application of collagen across various sectors, including food and beverages, healthcare, and cosmetics.[1] Cosmetics industry contributed significantly to market expansion, with rising consumer demand for beauty products incorporating collagen for its anti-aging properties.[2]

Key Points: 
  • [2]
    Regionally, the market is strongest in Asia, particularly in countries like Japan and South Korea, where collagen tripeptide supplements are trending.
  • Type II collagen supports cartilage and joint health, while Type III collagen forms the structural framework of organs and blood vessels.
  • Unlike conventional larger collagen peptides (100 to 1000 amino acids), collagen tripeptides have up to 50% better absorption rate than regular collagen peptides.
  • [8]
    TCI Biotech LLC has introduced Maxi Collagen™, a cutting-edge third-generation small molecular collagen tripeptide, designed to meet the rapidly increasing demand for advanced functional collagen beverages.

Abvance Therapeutics Announces $3.9M Program Related Investment from the Helmsley Charitable Trust to Support Development of Its Novel Insulin and Glucagon Combined Formulation

Retrieved on: 
Tuesday, September 10, 2024
Fear, Patient, Therapy, T1D, Biomedical engineering, Blood, Helmsley, Doctor of Philosophy, Seizure, Death, Peptide, Hypoglycemia, Coma, Vanderbilt University, KOL, Biophysics, Diabetes, Risk, Insulin, Plasma, American Diabetes Association, Glucagon, MD, Pharmaceutical industry

The funding is non-dilutive and will support the pre-clinical development of ABV100, the Company’s initial proprietary insulin-glucagon combination candidate.

Key Points: 
  • The funding is non-dilutive and will support the pre-clinical development of ABV100, the Company’s initial proprietary insulin-glucagon combination candidate.
  • Despite advances in diabetes technology, hypoglycemia occurs frequently and can be serious, resulting in seizure, coma, and death.
  • The cost of direct medical treatment for severe hypoglycemia remains significant, as do the indirect costs of lost productivity for affected individuals.
  • It will help our team advance the development of ABV100,” stated David Maggs, MD co-founder and CEO of Abvance Therapeutics.

New Meta-Analysis Shows Treos Bio’s Promiscuous Epitopes in Their Off-The-Shelf Colorectal Cancer Immunotherapy Produce Stronger Immune Response than Traditional Epitopes

Retrieved on: 
Monday, September 9, 2024
ESMO, Colorectal cancer, Genetics, MSS, Poster, Immunotherapy, Allele, Immunology, Palm Treo, Genotype, Meta-analysis, Research, Oncology, Patient, Epitope, Peptide, HLA, Vaccine

The analysis revealed that prioritized peptides, selected using Treos' proprietary computational technology, were key in driving immune responses and clinical outcomes across the studies.

Key Points: 
  • The analysis revealed that prioritized peptides, selected using Treos' proprietary computational technology, were key in driving immune responses and clinical outcomes across the studies.
  • The results will be presented in a poster session at the 2024 European Society of Medical Oncology (ESMO) annual meeting in Barcelona on September 15.
  • The poster, titled "149P - Evaluation of HLA Genotype as a Predictive Biomarker for Immunological and Clinical Responses to PolyPEPI1018 Cancer Vaccine in Colorectal Cancer," will detail these findings.
  • “For the first time, our data shows how these multi-peptide immune responses are connected to patients' HLA genetics, the key driver behind patient heterogeneity and varying responses to cancer immunotherapies,” she said.

Carmell Corporation Launches Skincare Partnership With Ladies Playbook to Support and Celebrate NFL Sports Community

Retrieved on: 
Thursday, September 5, 2024
Social media, Woman, Health, Peptide, Excipient, Foul, Growth, Partnership, Skin, Biology, Protein, Education, NFL, Day

This partnership comes as the new NFL season kicks into full gear and as Carmell aims to accelerate the growth of its flagship brand, Carmell Secretome™, through the expansion of its direct-to-consumer and e-commerce customer channels as well as driving toward influential franchise initiatives like Ladies Playbook.

Key Points: 
  • This partnership comes as the new NFL season kicks into full gear and as Carmell aims to accelerate the growth of its flagship brand, Carmell Secretome™, through the expansion of its direct-to-consumer and e-commerce customer channels as well as driving toward influential franchise initiatives like Ladies Playbook.
  • “After spending 11 years in the NFL, I created Ladies Playbook as a space to help other women find all their needs conveniently in one place.
  • Our partnership with Carmell enables NFL Ladies an opportunity to enhance their own skin health through bio-aesthetic derived products and the local MedSpa community,” said Atoya Burleson, Founder of Ladies Playbook.
  • Furthering its commitment, Carmell and Ladies Playbook will also build omni-channel opportunities to feature both brands across social media, ladiesplaybook.com, carmellsecretome.com and digital platforms leading to the Ladies Playbook Awards in New Orleans – Super Bowl LIX.

Biostimulants Market to Grow by USD 1.74 Billion (2024-2028) as Agricultural Demand Rises, How AI is Transforming the Market, Technavio Report

Retrieved on: 
Wednesday, September 4, 2024
Soil, Population growth, Nucleotide, TFP, AI, Nitrate, Iron, Peptide, Research, Silicon, Phosphorus, Nucleoside, Vegetable, Sugar, Zinc, Fertilizer, Water, Micronutrient, Nutrient, Growth, Malnutrition, Farmer, Vitamin, Protein, Magnesium, Plant, Germination, Water retention, Lipid, Ground substance, Biopolymer, Agriculture, Dicarboxylic acid, Crop protection

Biostimulants offer a solution by improving crop yield, making them an essential tool for farmers.

Key Points: 
  • Biostimulants offer a solution by improving crop yield, making them an essential tool for farmers.
  • The market for biostimulants is poised to grow as the demand for food increases and arable land continues to shrink.
  • The Biostimulants Market is experiencing significant growth, particularly in the agriculture sector.
  • Key trends include the use of biostimulants in oilseeds and pulses, durum wheat, and podded crops.

SARAH CREAL ANNOUNCES SEPHORA LAUNCH CALLING IN THE NEW AGE OF LUXURY BEAUTY

Retrieved on: 
Tuesday, September 3, 2024
Cream, Woman, Judgement, Veganism, WOMEN, CGC, Reflexive pronoun, Pink tax, Partnership, Skin, Speak for Yourself, Gluten-free diet, Double standard, Women's rights, Peptide, Cruelty-free, Life, Interview, Lip, SPF, Concealer, Cab, Collection, Cosmetics

NEW YORK, Sept. 3, 2024 /PRNewswire/ -- Sarah Creal announces its launch into 22 doors nationwide at Sephora and on Sephora.com. The luxury beauty brand founded by Sarah Creal, a visionary Product Developer and Brand Builder of 30 years, features high performance makeup and skincare essentials for women 40+.

Key Points: 
  • NEW YORK, Sept. 3, 2024 /PRNewswire/ -- Sarah Creal announces its launch into 22 doors nationwide at Sephora and on Sephora.com.
  • The luxury beauty brand founded by Sarah Creal, a visionary Product Developer and Brand Builder of 30 years, features high performance makeup and skincare essentials for women 40+.
  • Sarah Creal clinically tests every product with third party labs and presents all products in considered, bespoke packaging.
  • Sarah Creal launches on Sephora.com September 3rd, with an in-store rollout in 22 doors starting September 4th.

Justin Baldoni’s doctor available to comment on “It Ends With Us” actor/director receiving groundbreaking regenerative therapy to treat chronic pain

Retrieved on: 
Wednesday, August 28, 2024
Movement, Injection, B cell, Comment, Injury, Athlete, Peptide, Chronic pain, Longevity, Cartilage, Pain, Arthritis, Communication, NP-hardness, Meniscus, Spinal disc herniation, PR, Patient, Regenerative medicine, Shoulder, Dentistry

MISSISSAUGA, Ontario, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Justin Baldoni’s doctor, Dr. Adeel Khan, is available to comment on treating the “It Ends With Us” star for chronic knee and shoulder pain using cutting-edge regenerative therapy.

Key Points: 
  • MISSISSAUGA, Ontario, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Justin Baldoni’s doctor, Dr. Adeel Khan, is available to comment on treating the “It Ends With Us” star for chronic knee and shoulder pain using cutting-edge regenerative therapy.
  • But Baldoni, who both acted and directed the film, was suffering through a lot of pain when production began in May 2023.
  • Baldoni has endured a number of injuries, including a herniated disk, damaged meniscus and cartilage in both knees, and arthritis in his shoulder.
  • "When Justin came to see me, he had been suffering from chronic pain for years,” says Dr. Khan.

Emergex Receives Patent Protection for First-in-Class Influenza A Vaccines with Potential to Provide Long-Term T Cell Immunity

Retrieved on: 
Thursday, August 22, 2024
Invention, Epitope, Immunoproteomics, CD8, MHC, Influenza, Patent, Radio spectrum, Research, Influenza A virus, Entrepreneurship, Vaccination, Peptide, Vaccine

This groundbreaking patent covers Emergex’s vaccine comprising in part immunogenic peptides encoded by a negative sense open reading frame (ORF) from segment 8 of the influenza A genome.

Key Points: 
  • This groundbreaking patent covers Emergex’s vaccine comprising in part immunogenic peptides encoded by a negative sense open reading frame (ORF) from segment 8 of the influenza A genome.
  • Additionally, incorporation of avian- and equine species-specific NEG8 derived peptides in a vaccine also has the potential to expand protection to zoonotic transmissions.
  • Professor Thomas Rademacher, Co-Founder and Chief Executive Officer at Emergex, commented: "Our research into NEG8 has revealed exciting potential for a new approach to influenza vaccines.
  • Emergex is set to advance its first-in-class influenza vaccine into the clinic, with Phase I trials anticipated to begin in the first half of 2025.